Maze Therapeutics CSBO sells 7,500 shares after exercise
Maze Therapeutics CSBO Atul Dandekar executed an option exercise and share sale.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Maze Therapeutics CSBO Atul Dandekar executed an option exercise and share sale. On June 29, he exercised 7,500 stock options at $10.42 per share and sold 7,500 shares of common stock at $28.02 per share in an open-market transaction.
These trades were made under a pre-arranged Rule 10b5-1 trading plan. Following the sale, he holds 26,250 shares of common stock directly, including 1,442 shares acquired through the company’s Employee Stock Purchase Plan.
Insider Trade Summary 10b5-1
Exercise and Sale: 7,500 shares ($132K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Dandekar Atul
Role
CSBO
Sold
7,500 shs ($210K)
Approx. gross sale proceeds
$210K
Approx. exercise cost
$78K
Approx. pre-tax spread
$132K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 7,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 7,500 | $10.42 | $78K |
| Sale | Common Stock | 7,500 | $28.02 | $210K |
Holdings After Transaction:
Stock Option (Right to Buy) — 29,143 contracts (Direct);
Common Stock — 26,250 shares (Direct)
Footnotes (3)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 29, 2025.
- F2. The reported total includes 1,442 shares of the Issuer's Common Stock acquired by the reporting person in one or more transactions with the Issuer pursuant to its Employee Stock Purchase Plan, which transactions are exempt pursuant to Rules 16a3(f)(1)(i)(B) and 16b3(c).
- F3. The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on March 17, 2025.
Key Figures
Shares sold: 7,500 shares
Sale price: $28.02/share
Options exercised: 7,500 shares
+3 more
6 metrics
Shares sold
7,500 shares
Common Stock sold on June 29 at $28.02 per share
Sale price
$28.02/share
Price for 7,500 Maze Therapeutics common shares sold
Options exercised
7,500 shares
Stock options exercised into common stock on June 29
Exercise price
$10.42/share
Conversion or exercise price of stock options
Shares held after
26,250 shares
Direct Maze Therapeutics common stock holdings after transactions
Options position after
29,143 options
Stock Option (Right to Buy) total following derivative transaction
Key Terms
Rule 10b5-1 trading plan, Employee Stock Purchase Plan, Stock Option (Right to Buy), open-market sale
4 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"shares of the Issuer's Common Stock acquired by the reporting person pursuant to its Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) listed as a derivative security with an expiration date in 2031"
open-market sale financial
"transaction_action is described as an open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Maze Therapeutics (MAZE) CSBO Atul Dandekar do in this Form 4?
Maze Therapeutics CSBO Atul Dandekar exercised 7,500 stock options and sold 7,500 common shares. Both transactions occurred on June 29 and were reported as an option exercise followed by an open-market sale under a pre-arranged Rule 10b5-1 trading plan.
What options did the Maze Therapeutics (MAZE) CSBO exercise in this filing?
He exercised stock options for 7,500 shares of Maze Therapeutics common stock at an exercise price of $10.42 per share. The filing notes the option award was fully vested, with vesting completed on March 17, 2025, before this transaction.
Were the Maze Therapeutics (MAZE) insider transactions pre-planned under Rule 10b5-1?
Yes. The filing states the sale transaction was effected under a Rule 10b5-1 trading plan adopted by Atul Dandekar on September 29, 2025. Such plans schedule trades in advance, making the timing more routine and less discretionary.
AI-generated analysis. How Rhea-AI works. Not financial advice.
